Medindia

X

American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience

Thursday, September 17, 2009 General News J E 4
Advertisement


BETHESDA, Md., Sept. 16 American Capital Ltd. (Nasdaq: ACAS) announced today that on September 15, it completed the sale of its portfolio company Axygen BioScience Inc., including its subsidiaries Axygen Inc. and Sorenson BioScience Inc., to Corning Incorporated for approximately $400 million. The total inception to date gain and income, including dividend and fee income, from the equity invested by American Capital's affiliated funds under management was $102 million, representing a 25% compounded annual rate of return. American Capital received $182 million in proceeds and realized a gain of $35 million from the transaction, subject to post-closing adjustments. American Capital's total inception to date realized gains on this investment were $36 million and its compounded annual rate of return, including interest and fees earned over the life of its investment was 22%. Including investments in Axygen BioScience by American Capital's affiliated funds under management, the inception to date realized gains were $61 million and the compounded annual rate of return was 22%. The proceeds received by American Capital were less than the second quarter 2009 valuation of the investment by $1 million, or less than 1%.



"Since the beginning of the fourth quarter of 2008, we've received approximately $875 million of proceeds from realizations of portfolio investment repayments and exits, including over 20 exits of portfolio companies," said Darin Winn, Senior Vice President and Senior Managing Director. "We are particularly pleased that all of our exits of control companies have been at enterprise multiples equal to or higher than our entry multiples."



Axygen BioScience is a leading manufacturer and distributor of high quality life sciences plastic consumables, liquid handling products and bench-top laboratory equipment.



"Over our three year investment in Axygen Bioscience, we have developed a great partnership with the management team and assisted in adding value to the company, enabling it to surpass its competition through growth and acquisitions," said Frank Do, Managing Director, Buyouts. "We are extremely proud of the company's improvements and success, which made it an attractive purchase for Corning Incorporated. The $35 million gain and 22% return on the Axygen Bioscience investment is an outstanding outcome for American Capital and its shareholders and a testament to our investment and exit strategies."



"The last few years have been exciting and rewarding for Axygen Bioscience and we are happy to have been a part of its success. The company successfully completed and integrated strategic acquisitions and partnerships, recorded robust financial performance and successfully launched new products," said Kimberly Reed, Principal, Buyouts. "We believe that moving forward, Corning's operational and financial support will enable Axygen Bioscience to secure a leading position in its industry."



American Capital invested in the One Stop Buyout(TM) of Axygen Inc. in September 2006. American Capital's investment took the form of a revolving credit facility, senior term loan, senior and junior subordinated debt and equity. In a series of transactions from November 2008 through March 2009, a new holding company, Axygen BioScience, was formed to include Axygen, Sorenson BioScience and Articles De Laboratoire De Precision (ALP). For more information about American Capital's original investment in Axygen, please go to http://www.americancapital.com/our_portfolio/companies/axygen.html.



Since American Capital's August 1997 IPO through the second quarter of 2009, the company has earned a 15% compounded annual return, including interest, dividends, fees and net gains, on 264 realizations of senior debt, subordinated debt and equity investments, totaling $12 billion of committed capital. These realizations represent 49% of all amounts invested by American Capital since its August 1997 IPO. Proceeds from these realizations exceeded the total associated prior quarter valuation of the investments by less than 1%. American Capital earned a 30% compounded annual return on the exit of its equity investments, including dividends, fees and net gains.



For a chart showing American Capital's exited portfolio companies, please go to http://www.americancapital.com/our_portfolio/exited.html.



ABOUT AMERICAN CAPITAL

American Capital is a publicly traded private equity firm and global asset manager. American Capital, both directly and through its asset management business, originates, underwrites and manages investments in middle market private equity, leveraged finance, real estate and structured products. Founded in 1986, American Capital has $11 billion(1) in capital resources under management and ten offices in the U.S., Europe and Asia. For further information, please refer to www.AmericanCapital.com.



(1) As of June 30, 2009.



Performance data quoted above represents past performance of American Capital. Past performance does not guarantee future results and the investment return and principal value of an investment in American Capital will likely fluctuate. Consequently, an investor's shares, when sold, may be worth more or less than their original cost. Additionally, American Capital's current performance may be lower or higher than the performance data quoted above.



This press release contains forward-looking statements. The statements regarding expected results of American Capital are subject to various factors and uncertainties, including the uncertainties associated with the timing of transaction closings, changes in interest rates, availability of transactions, changes in regional, national or international economic conditions or changes in the conditions of the industries in which American Capital has made investments.



Contact: Frank Do, Managing Director, Buyouts - (310) 806-6280 Kimberly Reed, Principal, Buyouts - (310) 806-6280 Brian Martin, Vice President, Buyouts - (310) 806-6280 Matthew Frankel, Vice President, Buyouts - (310) 806-6280 Media - (301) 968-9400

SOURCE American Capital Ltd.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Health Care Experts Discuss Nurse-Led Care Models ...
S
Available For Interviews: Howard Meitiner, Presid...